Clinical trial results:
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of LY2951742 in Patients with Episodic Migraine – the EVOLVE-2 Study

Summary

EudraCT number	2015-001882-17
Trial protocol	NL GB CZ DE ES
Global end of trial date	05 October 2018

Results information

Result version number	v1 (current)
This version publication date	18 October 2019
First version publication date	18 October 2019

Trial information

Trial identification

Sponsor protocol code	I5Q-MC-CGAH

Additional study identifiers

ISRCTN number	-
ClinicalTrials.gov id (NCT number)	NCT02614196
WHO universal trial number (UTN)	-
Other trial identifiers	Trial Number: 15768

Notes:

Sponsors

Sponsor organisation name	Eli Lilly and Company
Sponsor organisation address	Lilly Corporate Center, Indianapolis, IN, United States, 46285
Public contact	Available Mon Fri 9 AM 5 PM EST, Eli Lilly and Company, 1 877 CTLilly,
Scientific contact	Available Mon Fri 9 AM 5 PM EST, Eli Lilly and Company, 1 877 2854559,

Notes:

Paediatric regulatory details

Is trial part of an agreed paediatric investigation plan (PIP)	No
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial?	No
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial?	No

Notes:

Results analysis stage

Analysis stage	Final
Date of interim/final analysis	05 October 2018
Is this the analysis of the primary completion data?	No

Global end of trial reached?	Yes
Global end of trial date	05 October 2018
Was the trial ended prematurely?	No

Notes:

General information about the trial

Main objective of the trial:

The main purpose of this study is to evaluate the efficacy and safety of the study drug known as galcanezumab in participants with episodic migraine.

Protection of trial subjects:

This study was conducted in accordance with International Conference on Harmonization (ICH) Good Clinical Practice, and the principles of the Declaration of Helsinki, in addition to following the laws and regulations of the country or countries in which a study is conducted.

Background therapy: -

Evidence for comparator: -

Actual start date of recruitment	04 December 2015
Long term follow-up planned	No
Independent data monitoring committee (IDMC) involvement?	Yes

Notes:

Population of trial subjects

Subjects enrolled per country

Country: Number of subjects enrolled	Argentina: 44
Country: Number of subjects enrolled	Korea, Democratic People's Republic of: 98
Country: Number of subjects enrolled	Netherlands: 46
Country: Number of subjects enrolled	United States: 446
Country: Number of subjects enrolled	Czech Republic: 77
Country: Number of subjects enrolled	Taiwan: 58
Country: Number of subjects enrolled	Mexico: 71
Country: Number of subjects enrolled	United Kingdom: 15
Country: Number of subjects enrolled	Israel: 21
Country: Number of subjects enrolled	Germany: 75
Country: Number of subjects enrolled	Spain: 28
Worldwide total number of subjects	979
EEA total number of subjects	241

Notes:

Subjects enrolled per age group

In utero	0
Preterm newborn - gestational age < 37	0

wk	
Newborns (0-27 days)	0
Infants and toddlers (28 days-23 months)	0
Children (2-11 years)	0
Adolescents (12-17 years)	0
Adults (18-64 years)	975
From 65 to 84 years	4
85 years and over	0

Subject disposition

Recruitment

Recruitment details: -

Pre-assignment

Screening details:

Screening consisted of a full clinical assessment, including a comprehensive medical evaluation documenting medical history, and a physical and neurological examination.

Period 1

Period 1 title	Double blind Treatment Phase
Is this the baseline period?	Yes
Allocation method	Randomised - controlled
Blinding used	Double blind
Roles blinded	Subject, Investigator

Arms

Are arms mutually exclusive?	Yes
Arm title	Placebo

Arm description:

Participants received placebo by subcutaneous injection once a month for 6 months during double blind treatment phase.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants received placebo by subcutaneous injection once a month for 6 months.

Arm title	Galcanezumab 120mg

Arm description:

Participants received loading dose of 240mg galcanezumab at 1st dosing visit followed by 120mg galcanezumab once a month for 5 months by subcutaneous injection during double blind treatment phase.

Arm type	Experimental
Investigational medicinal product name	Galcanezumab
Investigational medicinal product code	
Other name	LY2951742
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants received loading dose of 240mg galcanezumab at 1st dosing visit followed by 120mg galcanezumab once a month for 5 months by subcutaneous injection.

Arm title	Galcanezumab 240mg

Arm description:

Participants received 240mg galcanezumab by subcutaneous injection once a month for 6 months during double blind treatment phase.

Arm type	Experimental

Investigational medicinal product name	Galcanezumab
Investigational medicinal product code	
Other name	LY2951742
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants received 240mg galcanezumab by subcutaneous injection once a month for 6 months.

Arm title	Placebo Maximum Extended Enrollment Cohort

Arm description:

Participants received placebo by subcutaneous injection once a month for 6 months during double blind treatment phase.

Arm type	Placebo
Investigational medicinal product name	Placebo
Investigational medicinal product code	
Other name	
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants received placebo by subcutaneous injection once a month for 6 months.

Arm title	Galcanezumab 120mg Maximum Extended Enrollment Cohort

Arm description:

Participants received loading dose of 240mg galcanezumab at 1st dosing visit followed by 120mg galcanezumab once a month for 5 months by subcutaneous injection during double blind treatment phase.

Arm type	Experimental
Investigational medicinal product name	Galcanezumab
Investigational medicinal product code	
Other name	LY2951742
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants received loading dose of 240mg galcanezumab at 1st dosing visit followed by 120mg galcanezumab once a month for 5 months by subcutaneous injection.

Arm title	Galcanezumab 240mg Maximum Extended Enrollment Cohort

Arm description:

Participants received 240mg galcanezumab by subcutaneous injection once a month for 6 months during double blind treatment phase.

Arm type	Experimental
Investigational medicinal product name	Galcanezumab
Investigational medicinal product code	
Other name	LY2951742
Pharmaceutical forms	Solution for injection in pre-filled syringe
Routes of administration	Subcutaneous use

Dosage and administration details:

Participants received 240mg galcanezumab by subcutaneous injection once a month for 6 months.

Number of subjects in period 1	Placebo	Galcanezumab 120mg	Galcanezumab 240mg
Started	461	231	223
Received at least one dose of study drug	461	231	223
Completed	387	203	195
Not completed	74	28	28
Physician decision	4	-	2
Consent withdrawn by subject	39	11	14
Adverse event, non-fatal	8	5	9
Terminated by sponsor	1	-	-
Pregnancy	1	2	-
Lost to follow-up	10	7	1
Lack of efficacy	6	1	1
Protocol deviation	5	2	1

Number of subjects in period 1	Placebo Maximum Extended Enrollment Cohort	Galcanezumab 120mg Maximum Extended Enrollment Cohort	Galcanezumab 240mg Maximum Extended Enrollment Cohort
Started	30	15	19
Received at least one dose of study drug	30	14	19
Completed	26	14	19
Not completed	4	1	0
Physician decision	-	-	-
Consent withdrawn by subject	4	-	-
Adverse event, non-fatal	-	-	-
Terminated by sponsor	-	-	-
Pregnancy	-	-	-
Lost to follow-up	-	-	-
Lack of efficacy	-	-	-
Protocol deviation	-	1	-

Period 2

Period 2 title	Post Treatment Follow-up Phase
Is this the baseline period?	No
Allocation method	Not applicable
Blinding used	Not blinded

Arms

Are arms mutually exclusive?	Yes

Arm title	Placebo
Arm description:	
Participants did not receive any intervention during post-treatment follow-up phase.	
Arm type	No intervention
No investigational medicinal product assigned in this arm	
Arm title	Galcanezumab 120mg
Arm description:	
Participants did not receive any intervention during post-treatment follow-up phase.	
Arm type	No intervention
No investigational medicinal product assigned in this arm	
Arm title	Galcanezumab 240mg
Arm description:	
Participants did not receive any intervention during post-treatment follow-up phase.	
Arm type	No intervention
No investigational medicinal product assigned in this arm	
Arm title	Placebo Maximum Extended Enrollment Cohort
Arm description:	
Participants did not receive any intervention during post-treatment follow-up phase.	
Arm type	No intervention
No investigational medicinal product assigned in this arm	
Arm title	Galcanezumab 120mg Maximum Extended Enrollment Cohort
Arm description:	
Participants did not receive any intervention during post-treatment follow-up phase.	
Arm type	No intervention
No investigational medicinal product assigned in this arm	
Arm title	Galcanezumab 240mg Maximum Extended Enrollment Cohort
Arm description:	
Participants did not receive any intervention during post-treatment follow-up phase.	
Arm type	No intervention
No investigational medicinal product assigned in this arm	

Number of subjects in period 2[1]	Placebo	Galcanezumab 120mg	Galcanezumab 240mg
Started	387	203	195
Completed	390	208	199
Not completed	20	5	8
Consent withdrawn by subject	10	1	5
Pregnancy	2	-	-
Lost to follow-up	8	3	3
Protocol deviation	-	1	-
Joined	23	10	12
Double blind discontinued subjects	23	10	12

Number of subjects in period 2[1]	Placebo Maximum Extended Enrollment Cohort	Galcanezumab 120mg Maximum Extended Enrollment Cohort	Galcanezumab 240mg Maximum Extended Enrollment Cohort
Started	25	14	19
Completed	24	13	19
Not completed	1	2	0
Consent withdrawn by subject	1	-	-
Pregnancy	-	-	-
Lost to follow-up	-	1	-
Protocol deviation	-	1	-
Joined	0	1	0
Double blind discontinued subjects	-	1	-

Notes:

[1] - The number of subjects starting the period is not consistent with the number completing the preceding period. It is expected the number of subjects starting the subsequent period will be the same as the number completing the preceding period.

Justification: Participants who discontinued double blind phase had an option to enter post treatment phase.

Baseline characteristics

Reporting groups	
Reporting group title	Placebo
Reporting group description:	
Participants received placebo by subcutaneous injection once a month for 6 months during double blind treatment phase.	
Reporting group title	Galcanezumab 120mg
Reporting group description:	
Participants received loading dose of 240mg galcanezumab at 1st dosing visit followed by 120mg galcanezumab once a month for 5 months by subcutaneous injection during double blind treatment phase.	
Reporting group title	Galcanezumab 240mg
Reporting group description:	
Participants received 240mg galcanezumab by subcutaneous injection once a month for 6 months during double blind treatment phase.	
Reporting group title	Placebo Maximum Extended Enrollment Cohort
Reporting group description:	
Participants received placebo by subcutaneous injection once a month for 6 months during double blind treatment phase.	
Reporting group title	Galcanezumab 120mg Maximum Extended Enrollment Cohort
Reporting group description:	
Participants received loading dose of 240mg galcanezumab at 1st dosing visit followed by 120mg galcanezumab once a month for 5 months by subcutaneous injection during double blind treatment phase.	
Reporting group title	Galcanezumab 240mg Maximum Extended Enrollment Cohort
Reporting group description:	
Participants received 240mg galcanezumab by subcutaneous injection once a month for 6 months during double blind treatment phase.	

Reporting group values	Placebo	Galcanezumab 120mg	Galcanezumab 240mg
Number of subjects	461	231	223
Age categorical Units: Subjects			
In utero Preterm newborn infants (gestational age < 37 wks) Newborns (0-27 days) Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years 85 years and over			
Age Continuous Units: years			
arithmetic mean	42.33	40.91	41.91
standard deviation	± 11.30	± 11.15	± 10.77
Gender categorical Units: Subjects			
Female	393	197	191

Male	68	34	32

Sex: Female, Male Units: Subjects			
Female	393	197	191
Male	68	34	32
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	118	58	61
Not Hispanic or Latino	318	162	151
Unknown or Not Reported	25	11	11
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	20	8	13
Asian	50	28	24
Native Hawaiian or Other Pacific Islander	0	0	2
Black or African American	36	11	16
White	325	166	152
More than one race	30	18	16
Unknown or Not Reported	0	0	0
Region of Enrollment Units: Subjects			
Argentina	22	12	10
South Korea	34	17	17
Netherlands	24	11	11
United States	224	112	110
Czechia	39	19	19
Taiwan	12	7	5
Mexico	36	18	17
United Kingdom	8	4	3
Israel	11	5	5
Germany	37	19	19
Spain	14	7	7
Migraine Headache Days (MHD) per month			
Migraine Headache Day (MHD):A calendar day on which a migraine headache or probable migraine headache occurred.			
Units: Days per Month			
arithmetic mean	9.19	9.07	9.06
standard deviation	± 2.99	± 2.87	± 2.92

Reporting group values	Placebo Maximum Extended Enrollment Cohort	Galcanezumab 120mg Maximum Extended Enrollment Cohort	Galcanezumab 240mg Maximum Extended Enrollment Cohort
Number of subjects	30	15	19
Age categorical Units: Subjects			
In utero			
Preterm newborn infants (gestational age < 37 wks)			
Newborns (0-27 days)			

Infants and toddlers (28 days-23 months) Children (2-11 years) Adolescents (12-17 years) Adults (18-64 years) From 65-84 years 85 years and over			
Age Continuous Units: years			
arithmetic mean	45.37	39.40	42.58
standard deviation	± 10.30	± 11.58	± 11.13
Gender categorical Units: Subjects			
Female	22	13	14
Male	8	2	5
Sex: Female, Male Units: Subjects			
Female	22	13	14
Male	8	2	5
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	4	2	3
Not Hispanic or Latino	21	10	12
Unknown or Not Reported	5	3	4
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	0	0	0
Asian	30	15	19
Native Hawaiian or Other Pacific Islander	0	0	0
Black or African American	0	0	0
White	0	0	0
More than one race	0	0	0
Unknown or Not Reported	0	0	0
Region of Enrollment Units: Subjects			
Argentina	0	0	0
South Korea	14	7	9
Netherlands	0	0	0
United States	0	0	0
Czechia	0	0	0
Taiwan	16	8	10
Mexico	0	0	0
United Kingdom	0	0	0
Israel	0	0	0
Germany	0	0	0
Spain	0	0	0
Migraine Headache Days (MHD) per month			
Migraine Headache Day (MHD):A calendar day on which a migraine headache or probable migraine headache occurred.			
Units: Days per Month			
arithmetic mean	9.16	9.06	9.01

standard deviation	± 2.98	± 2.86	± 2.90

Reporting group values	Total		
Number of subjects	979		
Age categorical Units: Subjects			
In utero	0		
Preterm newborn infants (gestational age < 37 wks)	0		
Newborns (0-27 days)	0		
Infants and toddlers (28 days-23 months)	0		
Children (2-11 years)	0		
Adolescents (12-17 years)	0		
Adults (18-64 years)	0		
From 65-84 years	0		
85 years and over	0		
Age Continuous Units: years			
arithmetic mean			
standard deviation	-		
Gender categorical Units: Subjects			
Female	830		
Male	149		
Sex: Female, Male Units: Subjects			
Female	830		
Male	149		
Ethnicity (NIH/OMB) Units: Subjects			
Hispanic or Latino	246		
Not Hispanic or Latino	674		
Unknown or Not Reported	59		
Race (NIH/OMB) Units: Subjects			
American Indian or Alaska Native	41		
Asian	166		
Native Hawaiian or Other Pacific Islander	2		
Black or African American	63		
White	643		
More than one race	64		
Unknown or Not Reported	0		
Region of Enrollment Units: Subjects			
Argentina	44		
South Korea	98		
Netherlands	46		
United States	446		

Czechia	77		
Taiwan	58		
Mexico	71		
United Kingdom	15		
Israel	21		
Germany	75		
Spain	28		
Migraine Headache Days (MHD) per month			
Migraine Headache Day (MHD):A calendar day on which a migraine headache or probable migraine headache occurred.			
Units: Days per Month			
arithmetic mean			
standard deviation	-		

End points

End points reporting groups

Reporting group title	Placebo
Reporting group description:	
Participants received placebo by subcutaneous injection once a month for 6 months during double blind treatment phase.	
Reporting group title	Galcanezumab 120mg
Reporting group description:	
Participants received loading dose of 240mg galcanezumab at 1st dosing visit followed by 120mg galcanezumab once a month for 5 months by subcutaneous injection during double blind treatment phase.	
Reporting group title	Galcanezumab 240mg
Reporting group description:	
Participants received 240mg galcanezumab by subcutaneous injection once a month for 6 months during double blind treatment phase.	
Reporting group title	Placebo Maximum Extended Enrollment Cohort
Reporting group description:	
Participants received placebo by subcutaneous injection once a month for 6 months during double blind treatment phase.	
Reporting group title	Galcanezumab 120mg Maximum Extended Enrollment Cohort
Reporting group description:	
Participants received loading dose of 240mg galcanezumab at 1st dosing visit followed by 120mg galcanezumab once a month for 5 months by subcutaneous injection during double blind treatment phase.	
Reporting group title	Galcanezumab 240mg Maximum Extended Enrollment Cohort
Reporting group description:	
Participants received 240mg galcanezumab by subcutaneous injection once a month for 6 months during double blind treatment phase.	
Reporting group title	Placebo
Reporting group description:	
Participants did not receive any intervention during post-treatment follow-up phase.	
Reporting group title	Galcanezumab 120mg
Reporting group description:	
Participants did not receive any intervention during post-treatment follow-up phase.	
Reporting group title	Galcanezumab 240mg
Reporting group description:	
Participants did not receive any intervention during post-treatment follow-up phase.	
Reporting group title	Placebo Maximum Extended Enrollment Cohort
Reporting group description:	
Participants did not receive any intervention during post-treatment follow-up phase.	
Reporting group title	Galcanezumab 120mg Maximum Extended Enrollment Cohort
Reporting group description:	
Participants did not receive any intervention during post-treatment follow-up phase.	
Reporting group title	Galcanezumab 240mg Maximum Extended Enrollment Cohort
Reporting group description:	
Participants did not receive any intervention during post-treatment follow-up phase.	

Primary: Overall Mean Change from Baseline in the Number of Monthly Migraine Headache Days

End point title	Overall Mean Change from Baseline in the Number of Monthly Migraine Headache Days[1]

End point description:

Migraine Headache Day (MHD):A calendar day on which a migraine headache or probable migraine headache occurred.
Migraine Headache : A headache, with or without aura, of ≥30 minutes duration with both of the following required features (A and B):
A) At least 2 of the following headache characteristics: Unilateral location; Pulsatile quality; Moderate or severe pain intensity; Aggravation by or causing avoidance of routine physical activity;
AND
B) During headache at least one of the following: Nausea and/or vomiting; Photophobia and phonophobia;

Overall mean is derived from the average of months 1 to 6 from mixed model repeated measures (MMRM) model. Least Square (LS) mean was calculated using mixed model repeated measures (MMRM) model with treatment, pooled country, month, and treatment by month, baseline, and baseline by month as fixed effects.
APD: All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline value.

End point type	Primary

End point timeframe:

Baseline, Month 1 through Month 6

Notes:

[1] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Per Protocol, Statistical Analysis was not planned.

End point values	Placebo	Galcanezumab 120mg	Galcanezumab 240mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	450	226	220	
Units: Days Per Month				
least squares mean (standard error)	-2.28 (± 0.20)	-4.29 (± 0.25)	-4.18 (± 0.26)	

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Galcanezumab 120mg v Placebo
Number of subjects included in analysis	676
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LSMean Difference
Point estimate	-2.02
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.55
upper limit	-1.48
Variability estimate	Standard error of the mean
Dispersion value	0.27

Statistical analysis title	Statistical Analysis 2
Comparison groups	Placebo v Galcanezumab 240mg
Number of subjects included in analysis	670
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LSMean Difference
Point estimate	-1.9
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.44
upper limit	-1.36
Variability estimate	Standard error of the mean
Dispersion value	0.27

Secondary: Mean Percentage of Participants with Reduction from Baseline ≥50%, ≥75%, and 100% in Monthly Migraine Headache Days

End point title	Mean Percentage of Participants with Reduction from Baseline ≥50%, ≥75%, and 100% in Monthly Migraine Headache Days[2]

End point description:

Migraine Headache Day (MHD): A calendar day on which a migraine headache or probable migraine headache occurred.

Mean is derived from the average of months 1 to 6 from generalized linear mixed model repeated measures. Mean percentages of participants were calculated with a generalized linear mixed model repeated measures method with treatment, month and treatment by month, and baseline as model terms.

Analysis Population Description: All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline value.

End point type	Secondary

End point timeframe:

Baseline, Month 1 through Month 6

Notes:

[2] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Per Protocol, Statistical Analysis was not planned.

End point values	Placebo	Galcanezumab 120mg	Galcanezumab 240mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	450	226	220	
Units: percentage of participants				
arithmetic mean (standard error)				
≥50%	36 (± 1.7)	59.3 (± 2.4)	56.5 (± 2.5)	
≥75%	17.8 (± 1.3)	33.5 (± 2.3)	34.3 (± 2.3)	

100%	5.7 (± 0.7)	11.5 (± 1.4)	13.8 (± 1.5)	

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Statistical analysis description: Reduction from Baseline ≥50%	
Comparison groups	Placebo v Galcanezumab 120mg
Number of subjects included in analysis	676
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Odds ratio (OR)
Point estimate	2.6
Confidence interval	
level	95 %
sides	2-sided
lower limit	2.03
upper limit	3.32

Statistical analysis title	Statistical Analysis 2
Statistical analysis description: Reduction from Baseline ≥50%	
Comparison groups	Placebo v Galcanezumab 240mg
Number of subjects included in analysis	670
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Odds ratio (OR)
Point estimate	2.31
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.81
upper limit	2.96

Statistical analysis title	Statistical Analysis 3
Statistical analysis description: Reduction from Baseline ≥75%	
Comparison groups	Placebo v Galcanezumab 120mg

Number of subjects included in analysis	676
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Odds ratio (OR)
Point estimate	2.34
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.78
upper limit	3.06

Statistical analysis title	Statistical Analysis 4
Statistical analysis description: Reduction from Baseline ≥75%	
Comparison groups	Placebo v Galcanezumab 240mg
Number of subjects included in analysis	670
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Odds ratio (OR)
Point estimate	2.42
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.84
upper limit	3.17

Statistical analysis title	Statistical Analysis 5
Statistical analysis description: Reduction from Baseline ≥100%	
Comparison groups	Placebo v Galcanezumab 120mg
Number of subjects included in analysis	676
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Odds ratio (OR)
Point estimate	2.16
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.5
upper limit	3.12

Statistical analysis title	Statistical Analysis 6
Statistical analysis description: Reduction from Baseline ≥100%	

Comparison groups	Placebo v Galcanezumab 240mg
Number of subjects included in analysis	670
Analysis specification	Pre-specified
Analysis type	superiority
Parameter estimate	Odds ratio (OR)
Point estimate	2.67
Confidence interval	
level	95 %
sides	2-sided
lower limit	1.87
upper limit	3.81

Secondary: Mean Change from Baseline in the Migraine-Specific Quality of Life Questionnaire (MSQ) Version 2.1 Role Function Restrictive Domain

End point title	Mean Change from Baseline in the Migraine-Specific Quality of Life Questionnaire (MSQ) Version 2.1 Role Function Restrictive Domain[3]

End point description:

MSQ v2.1 was developed to address physical & emotional limitations of specific concern to individuals with migraine.
It consists of 14 items that address 3 domains:(1) Role Function-Restrictive (items 1-7);(2) Role Function- Preventive (items 8-11);&(3) Emotional Function (items 12-14).Response options range from "none of the time" (value 1) to "all of the time" (value 6), & are reverse-recoded (value 6 to 1) before the domain scores are calculated.Total raw scores for each domain is the sum of the final item value for all of the items in that domain.After the total raw score is computed for each domain and, they are transformed to a 0-100 scale with higher scores indicating a better health status & a positive change in scores reflecting functional improvement.
Mean is derived from the average of months 4 to 6 from MMRM model. LSMean was calculated using MMRM model with treatment, pooled country, month, treatment by month, baseline by month & baseline MHD category as fixed factors.

End point type	Secondary

End point timeframe:

Baseline, Month 4 through Month 6

APD: All randomized participants who received at least one dose of study drug and had baseline & at least one post baseline value.

Notes:

[3] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Per Protocol, Statistical Analysis was not planned.

End point values	Placebo	Galcanezumab 120mg	Galcanezumab 240mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	443	226	219	
Units: units on a scale				
least squares mean (standard error)	19.65 (± 0.92)	28.47 (± 1.15)	27.04 (± 1.17)	

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Placebo v Galcanezumab 120mg

Number of subjects included in analysis	669
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LSMean Difference
Point estimate	8.82
Confidence interval	
level	95 %
sides	2-sided
lower limit	6.33
upper limit	11.31
Variability estimate	Standard error of the mean
Dispersion value	1.27

Statistical analysis title	Statistical Analysis 2
Comparison groups	Placebo v Galcanezumab 240mg
Number of subjects included in analysis	662
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LSMean Difference
Point estimate	7.39
Confidence interval	
level	95 %
sides	2-sided
lower limit	4.88
upper limit	9.9
Variability estimate	Standard error of the mean
Dispersion value	1.28

Secondary: Overall Mean Change from Baseline in the Number of Monthly Migraine Headache Days Requiring Medication for the Acute Treatment of Migraine or Headache

End point title	Overall Mean Change from Baseline in the Number of Monthly Migraine Headache Days Requiring Medication for the Acute Treatment of Migraine or Headache[4]

End point description:

Migraine Headache Day (MHD):A calendar day on which a migraine headache or probable migraine headache occurred.

Overall mean is derived from the average of months 1 to 6 from MMRM model.LSMean was calculated using MMRM model with treatment, pooled country, month, treatment by month, baseline, baseline by month, and baseline MHD category as fixed effects.

APD: All randomized participants who received at least one dose of study drug and had baseline and post baseline value.

End point type	Secondary

End point timeframe:

Baseline, Month 1 through Month 6

Notes:

[4] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Per Protocol, Statistical Analysis was not planned.

End point values	Placebo	Galcanezumab 120mg	Galcanezumab 240mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	450	226	220	
Units: Medication Used Days				
least squares mean (standard error)	-1.85 (± 0.18)	-3.67 (± 0.22)	-3.63 (± 0.23)	

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Placebo v Galcanezumab 120mg
Number of subjects included in analysis	676
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LSMean Difference
Point estimate	-1.82
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.29
upper limit	-1.36
Variability estimate	Standard error of the mean
Dispersion value	0.24

Statistical analysis title	Statistical Analysis 2
Comparison groups	Placebo v Galcanezumab 240mg
Number of subjects included in analysis	670
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LSMean Difference
Point estimate	-1.78
Confidence interval	
level	95 %
sides	2-sided
lower limit	-2.25
upper limit	-1.31

Variability estimate	Standard error of the mean
Dispersion value	0.24

Secondary: Mean Change from Baseline in Patient Global Impression of Severity (PGI-S) Rating

End point title	Mean Change from Baseline in Patient Global Impression of Severity (PGI-S) Rating[5]

End point description:

The PGI-S scale is a participant-rated instrument that measures patients own global impression of their illness severity. The participant was instructed as follows: "Considering migraine as a chronic condition, how would you rate your level of illness?" Response options were from 1 ("normal, not at all ill") to 7 ("extremely ill"). Mean is derived from the average of months 4 to 6 from MMRM model. LSMean was calculated using MMRM model with treatment, pooled country, month, treatment by month, baseline, baseline by month, and baseline MHD category as fixed factors.

APD: All randomized participants who received at least one dose of study drug and had baseline and post baseline value.

End point type	Secondary

End point timeframe:

Baseline, Month 4 through Month 6

Notes:

[5] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Per Protocol, Statistical Analysis was not planned.

End point values	Placebo	Galcanezumab 120mg	Galcanezumab 240mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	443	226	219	
Units: units on a scale				
least squares mean (standard error)	-0.94 (± 0.07)	-1.22 (± 0.08)	-1.17 (± 0.08)	

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Placebo v Galcanezumab 120mg
Number of subjects included in analysis	669
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.002
Method	Mixed models analysis
Parameter estimate	LSMean Difference
Point estimate	-0.29
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.47
upper limit	-0.11
Variability estimate	Standard error of the mean
Dispersion value	0.09

Statistical analysis title	Statistical Analysis 2
Comparison groups	Placebo v Galcanezumab 240mg
Number of subjects included in analysis	662
Analysis specification	Pre-specified
Analysis type	superiority
P-value	= 0.012
Method	Mixed models analysis
Parameter estimate	LSMean Difference
Point estimate	-0.23
Confidence interval	
level	95 %
sides	2-sided
lower limit	-0.41
upper limit	-0.05
Variability estimate	Standard error of the mean
Dispersion value	0.09

Secondary: Overall Mean Change from Baseline in Headache Hours

End point title	Overall Mean Change from Baseline in Headache Hours[6]

End point description:

Headache Hours is calculated as the total number of headache hours on which a headache occurred. Overall mean is derived from the average of months 1 to 6 from MMRM model. LSMean was calculated using MMRM model with treatment, pooled country, month, treatment by month, baseline, baseline by month and baseline MHD category.

APD: All randomized participants who received at least one dose of study drug and had baseline and at least one post baseline value.

End point type	Secondary

End point timeframe:

Baseline, Month 1 through Month 6

Notes:

[6] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Per Protocol, Statistical Analysis was not planned.

End point values	Placebo	Galcanezumab 120mg	Galcanezumab 240mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	450	226	220	
Units: Headache Hours per Month				
least squares mean (standard error)	-10.89 (± 1.92)	-26.07 (± 2.41)	-24.44 (± 2.44)	

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Placebo v Galcanezumab 120mg
Number of subjects included in analysis	676
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LSMean Difference
Point estimate	-15.19
Confidence interval	
level	95 %
sides	2-sided
lower limit	-20.27
upper limit	-10.11
Variability estimate	Standard error of the mean
Dispersion value	2.59

Statistical analysis title	Statistical Analysis 2
Comparison groups	Placebo v Galcanezumab 240mg
Number of subjects included in analysis	670
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LSMean Difference
Point estimate	-13.56
Confidence interval	
level	95 %
sides	2-sided
lower limit	-18.67
upper limit	-8.44
Variability estimate	Standard error of the mean
Dispersion value	2.6

Secondary: Mean Change from Baseline in the Migraine Disability Assessment Test (MIDAS) Total Score

End point title	Mean Change from Baseline in the Migraine Disability Assessment Test (MIDAS) Total Score[7]

End point description:

The MIDAS is a participant-rated scale which was designed to quantify headache-related disability over a 3-month period. This instrument consists of five items that reflect the number of days reported as missing or with reduced productivity at work or home, and the number of days of missed social events. Each item has a numeric response range from 0 to 90 days, if days are missed from work or home they are not counted as days with reduced productivity at work or home. The numeric responses are summed to produce a total score ranging from 0 to 270, in which a higher value is indicative of more disability. LSMean was calculated using MMRM model with treatment, pooled country, month, treatment by month, baseline, baseline by month, and baseline MHD category as fixed factors.

APD: All randomized participants who received at least one dose of study drug and had baseline and at

least one post baseline value.

End point type	Secondary

End point timeframe:

Baseline, Month 6

Notes:

[7] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Per Protocol, Statistical Analysis was not planned.

End point values	Placebo	Galcanezumab 120mg	Galcanezumab 240mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	409	216	215	
Units: units on a scale				
least squares mean (standard error)	-12.02 (± 1.27)	-21.17 (± 1.58)	-20.24 (± 1.62)	

Statistical analyses

Statistical analysis title	Statistical Analysis 1
Comparison groups	Galcanezumab 120mg v Placebo
Number of subjects included in analysis	625
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	LSMean Difference
Point estimate	-9.15
Confidence interval	
level	95 %
sides	2-sided
lower limit	-12.61
upper limit	-5.69
Variability estimate	Standard error of the mean
Dispersion value	1.76

Statistical analysis title	Statistical Analysis 2
Comparison groups	Placebo v Galcanezumab 240mg
Number of subjects included in analysis	624
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Mixed models analysis
Parameter estimate	Mean difference (final values)
Point estimate	-8.22

Confidence interval	
level	95 %
sides	2-sided
lower limit	-11.71
upper limit	-4.72
Variability estimate	Standard error of the mean
Dispersion value	1.78

Secondary: Percentage of Participants Developing Anti-drug Antibodies (ADA) to Galcanezumab

End point title	Percentage of Participants Developing Anti-drug Antibodies (ADA) to Galcanezumab[8]

End point description:

Treatment emergent (TE) ADA evaluable participant is considered to be TE ADA+ if the subject has at least one post-baseline titer that is a 4-fold or greater increase in titer from baseline measurement. If baseline result is ADA Not Present, then the participant is TE ADA+ if there is at least one post-baseline result of ADA present with titer >= 1: 20.

APD: All randomized participants who received at least one dose of study drug & had least one non-missing test result for ADA for each of the baseline period and the post-baseline period.

End point type	Secondary

End point timeframe:

Month 1 through Month 6

Notes:

[8] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Per Protocol, Statistical Analysis was not planned.

End point values	Placebo	Galcanezumab 120mg	Galcanezumab 240mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	443	222	214	
Units: percentage of participants				
number (not applicable)	0.45	8.56	5.14	

Statistical analyses

Statistical analysis title	Statistical Analysis 1

Statistical analysis description:

TE ADA Positive.

Comparison groups	Placebo v Galcanezumab 120mg
Number of subjects included in analysis	665
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Fisher exact

Statistical analysis title	Statistical Analysis 2
Statistical analysis description: TE ADA Positive	
Comparison groups	Placebo v Galcanezumab 240mg
Number of subjects included in analysis	657
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Fisher exact

Statistical analysis title	Statistical Analysis 3
Statistical analysis description: Neutralizing Antibodies	
Comparison groups	Placebo v Galcanezumab 120mg
Number of subjects included in analysis	665
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Fisher exact

Statistical analysis title	Statistical Analysis 4
Statistical analysis description: Neutralizing Antibodies	
Comparison groups	Placebo v Galcanezumab 240mg
Number of subjects included in analysis	657
Analysis specification	Pre-specified
Analysis type	superiority
P-value	< 0.001
Method	Fisher exact

Secondary: Pharmacokinetics (PK): Serum Concentrations of Galcanezumab

End point title	Pharmacokinetics (PK): Serum Concentrations of Galcanezumab[9]

End point description:

APD: All randomized participants who received at least one dose of study drug and had measurable serum concentrations.

End point type	Secondary

End point timeframe:

Month 6

Notes:

[9] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Per Protocol, Statistical Analysis was not planned.

End point values	Galcanezumab 120mg	Galcanezumab 240mg		
Subject group type	Reporting group	Reporting group		
Number of subjects analysed	194	193		
Units: Nanogram per milliliter (ng/mL)				
arithmetic mean (standard deviation)	17400 (± 8820)	32200 (± 12600)		

Statistical analyses

No statistical analyses for this end point

Secondary: Plasma Concentration of Calcitonin Gene-Related Peptide (CGRP)

End point title	Plasma Concentration of Calcitonin Gene-Related Peptide (CGRP)[10]

End point description:

APD: All randomized participants who had received at least one dose of study drug and had measurable plasma concentration.

End point type	Secondary

End point timeframe:

Month 6

Notes:

[10] - The end point is not reporting statistics for all the arms in the baseline period. It is expected all the baseline period arms will be reported on when providing values for an end point on the baseline period.
Justification: Per Protocol, Statistical Analysis was not planned.

End point values	Placebo	Galcanezumab 120mg	Galcanezumab 240mg	
Subject group type	Reporting group	Reporting group	Reporting group	
Number of subjects analysed	29	187	185	
Units: ng/mL				
arithmetic mean (standard deviation)	0.541 (± 1.11)	3.93 (± 1.83)	4.98 (± 1.60)	

Statistical analyses

No statistical analyses for this end point

Adverse events

Adverse events information

Timeframe for reporting adverse events:

Entire Study

Adverse event reporting additional description:

5 participants in Gal - 120mg treatment, 1 participant in Gal - 120mg post- treatment , & 1 participant in Gal - 120 mg treatment ME2 & 1 participant in Gal - 120mg post-treatment ME2 arms who discontinued after receiving loading dose of 240mg, these participants were included in Gal - 240mg treatment and post treatment equivalent ME2 arms.

Assessment type	Systematic

Dictionary used

Dictionary name	MedDRA
Dictionary version	20.1

Reporting groups

Reporting group title	Placebo - Treatment Phase
Reporting group description: -	
Reporting group title	Galcanezumab 120mg - Treatment Phase
Reporting group description: -	
Reporting group title	Galcanezumab 240mg - Treatment Phase
Reporting group description: -	
Reporting group title	Placebo - Post-treatment Phase
Reporting group description: -	
Reporting group title	Galcanezumab 120mg - Post-treatment Phase
Reporting group description: -	
Reporting group title	Galcanezumab 240mg - Post-treatment Phase
Reporting group description: -	
Reporting group title	Galcanezumab 120mg ME2 - Treatment Phase
Reporting group description: -	
Reporting group title	Placebo ME2 - Treatment Phase
Reporting group description: -	
Reporting group title	Galcanezumab 240mg ME2 - Treatment Phase
Reporting group description: -	
Reporting group title	Placebo ME2 - Post-treatment Phase
Reporting group description: -	
Reporting group title	Galcanezumab 120mg ME2 - Post-treatment Phase
Reporting group description: -	
Reporting group title	Galcanezumab 240mg ME2 - Post-treatment Phase

Reporting group description: -

Serious adverse events	Placebo - Treatment Phase	Galcanezumab 120mg - Treatment Phase	Galcanezumab 240mg - Treatment Phase
Total subjects affected by serious adverse events			
subjects affected / exposed	5 / 461 (1.08%)	5 / 226 (2.21%)	7 / 228 (3.07%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0

Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
adenocarcinoma of the cervix			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed[1]	0 / 393 (0.00%)	1 / 192 (0.52%)	0 / 196 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
uterine leiomyoma			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed[2]	0 / 393 (0.00%)	0 / 192 (0.00%)	0 / 196 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
pyrexia			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 461 (0.00%)	0 / 226 (0.00%)	1 / 228 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
nasal septum deviation			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 461 (0.00%)	0 / 226 (0.00%)	0 / 228 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
disorientation			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 461 (0.00%)	0 / 226 (0.00%)	1 / 228 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	1 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
panic attack			
alternative dictionary used: MedDRA 20.1			

subjects affected / exposed	0 / 461 (0.00%)	0 / 226 (0.00%)	0 / 228 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
post-traumatic stress disorder			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 461 (0.00%)	0 / 226 (0.00%)	0 / 228 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
suicide attempt			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	1 / 461 (0.22%)	0 / 226 (0.00%)	0 / 228 (0.00%)
occurrences causally related to treatment / all	1 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
foot fracture			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	1 / 461 (0.22%)	0 / 226 (0.00%)	0 / 228 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
meniscus injury			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 461 (0.00%)	0 / 226 (0.00%)	1 / 228 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
rib fracture			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	1 / 461 (0.22%)	0 / 226 (0.00%)	0 / 228 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
road traffic accident			
alternative dictionary used: MedDRA 20.1			

subjects affected / exposed	1 / 461 (0.22%)	0 / 226 (0.00%)	0 / 228 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
acute myocardial infarction			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 461 (0.00%)	0 / 226 (0.00%)	1 / 228 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
generalised tonic-clonic seizure			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 461 (0.00%)	0 / 226 (0.00%)	1 / 228 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
headache			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 461 (0.00%)	1 / 226 (0.44%)	0 / 228 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
migraine			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	1 / 461 (0.22%)	0 / 226 (0.00%)	0 / 228 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
transient ischaemic attack			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 461 (0.00%)	0 / 226 (0.00%)	1 / 228 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
gastritis			
alternative dictionary used: MedDRA 20.1			

subjects affected / exposed	0 / 461 (0.00%)	1 / 226 (0.44%)	0 / 228 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
haemorrhoids			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	1 / 461 (0.22%)	0 / 226 (0.00%)	0 / 228 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
rectal polyp			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 461 (0.00%)	1 / 226 (0.44%)	0 / 228 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
cholecystitis acute			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 461 (0.00%)	0 / 226 (0.00%)	0 / 228 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cholelithiasis			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 461 (0.00%)	0 / 226 (0.00%)	1 / 228 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
gallbladder polyp			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	1 / 461 (0.22%)	0 / 226 (0.00%)	0 / 228 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
bladder dysfunction			
alternative dictionary used: MedDRA 20.1			

subjects affected / exposed	0 / 461 (0.00%)	1 / 226 (0.44%)	0 / 228 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
goitre			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 461 (0.00%)	0 / 226 (0.00%)	0 / 228 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
arthralgia			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 461 (0.00%)	0 / 226 (0.00%)	0 / 228 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
patellofemoral pain syndrome			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 461 (0.00%)	0 / 226 (0.00%)	0 / 228 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
appendicitis			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 461 (0.00%)	0 / 226 (0.00%)	0 / 228 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
influenza			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 461 (0.00%)	0 / 226 (0.00%)	1 / 228 (0.44%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pyelonephritis			
alternative dictionary used: MedDRA 20.1			

subjects affected / exposed	0 / 461 (0.00%)	0 / 226 (0.00%)	0 / 228 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
urosepsis			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 461 (0.00%)	0 / 226 (0.00%)	0 / 228 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Placebo - Post-treatment Phase	Galcanezumab 120mg - Post-treatment Phase	Galcanezumab 240mg - Post-treatment Phase
Total subjects affected by serious adverse events			
subjects affected / exposed	3 / 410 (0.73%)	1 / 212 (0.47%)	3 / 208 (1.44%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
adenocarcinoma of the cervix			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed[1]	0 / 349 (0.00%)	0 / 179 (0.00%)	0 / 181 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
uterine leiomyoma			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed[2]	0 / 349 (0.00%)	1 / 179 (0.56%)	0 / 181 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
pyrexia			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 410 (0.00%)	0 / 212 (0.00%)	0 / 208 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			

nasal septum deviation			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 410 (0.00%)	0 / 212 (0.00%)	0 / 208 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
disorientation			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 410 (0.00%)	0 / 212 (0.00%)	0 / 208 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
panic attack			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 410 (0.00%)	0 / 212 (0.00%)	1 / 208 (0.48%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
post-traumatic stress disorder			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 410 (0.00%)	0 / 212 (0.00%)	1 / 208 (0.48%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
suicide attempt			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 410 (0.00%)	0 / 212 (0.00%)	0 / 208 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
foot fracture			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 410 (0.00%)	0 / 212 (0.00%)	0 / 208 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
meniscus injury			

alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 410 (0.00%)	0 / 212 (0.00%)	0 / 208 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
rib fracture			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 410 (0.00%)	0 / 212 (0.00%)	0 / 208 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
road traffic accident			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 410 (0.00%)	0 / 212 (0.00%)	0 / 208 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
acute myocardial infarction			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 410 (0.00%)	0 / 212 (0.00%)	0 / 208 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
generalised tonic-clonic seizure			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 410 (0.00%)	0 / 212 (0.00%)	0 / 208 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
headache			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 410 (0.00%)	0 / 212 (0.00%)	0 / 208 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
migraine			
alternative dictionary used: MedDRA 20.1			

subjects affected / exposed	0 / 410 (0.00%)	0 / 212 (0.00%)	0 / 208 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
transient ischaemic attack			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 410 (0.00%)	0 / 212 (0.00%)	0 / 208 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
gastritis			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 410 (0.00%)	0 / 212 (0.00%)	0 / 208 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
haemorrhoids			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 410 (0.00%)	0 / 212 (0.00%)	0 / 208 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
rectal polyp			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 410 (0.00%)	0 / 212 (0.00%)	0 / 208 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
cholecystitis acute			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 410 (0.00%)	0 / 212 (0.00%)	0 / 208 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cholelithiasis			
alternative dictionary used: MedDRA 20.1			

subjects affected / exposed	0 / 410 (0.00%)	0 / 212 (0.00%)	0 / 208 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
gallbladder polyp			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 410 (0.00%)	0 / 212 (0.00%)	0 / 208 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
bladder dysfunction			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 410 (0.00%)	0 / 212 (0.00%)	0 / 208 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
goitre			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	1 / 410 (0.24%)	0 / 212 (0.00%)	0 / 208 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
arthralgia			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 410 (0.00%)	0 / 212 (0.00%)	0 / 208 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
patellofemoral pain syndrome			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 410 (0.00%)	0 / 212 (0.00%)	1 / 208 (0.48%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 1
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
appendicitis			
alternative dictionary used: MedDRA 20.1			

subjects affected / exposed	1 / 410 (0.24%)	0 / 212 (0.00%)	0 / 208 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
influenza			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 410 (0.00%)	0 / 212 (0.00%)	0 / 208 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pyelonephritis			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	1 / 410 (0.24%)	0 / 212 (0.00%)	0 / 208 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
urosepsis			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	1 / 410 (0.24%)	0 / 212 (0.00%)	0 / 208 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Galcanezumab 120mg ME2 - Treatment Phase	Placebo ME2 - Treatment Phase	Galcanezumab 240mg ME2 - Treatment Phase
Total subjects affected by serious adverse events			
subjects affected / exposed	1 / 14 (7.14%)	1 / 30 (3.33%)	0 / 20 (0.00%)
number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
adenocarcinoma of the cervix			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed[1]	0 / 13 (0.00%)	0 / 22 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
uterine leiomyoma			
alternative dictionary used: MedDRA 20.1			

subjects affected / exposed[2]	0 / 13 (0.00%)	0 / 22 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
pyrexia			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 14 (0.00%)	0 / 30 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
nasal septum deviation			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 30 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
disorientation			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 14 (0.00%)	0 / 30 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
panic attack			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 14 (0.00%)	0 / 30 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
post-traumatic stress disorder			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 14 (0.00%)	0 / 30 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
suicide attempt			
alternative dictionary used: MedDRA 20.1			

subjects affected / exposed	0 / 14 (0.00%)	0 / 30 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
foot fracture			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 14 (0.00%)	0 / 30 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
meniscus injury			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 14 (0.00%)	0 / 30 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
rib fracture			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 14 (0.00%)	0 / 30 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
road traffic accident			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 14 (0.00%)	0 / 30 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
acute myocardial infarction			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 14 (0.00%)	0 / 30 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
generalised tonic-clonic seizure			
alternative dictionary used: MedDRA 20.1			

subjects affected / exposed	0 / 14 (0.00%)	0 / 30 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
headache			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 14 (0.00%)	0 / 30 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
migraine			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 14 (0.00%)	0 / 30 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
transient ischaemic attack			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 14 (0.00%)	0 / 30 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
gastritis			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 14 (0.00%)	0 / 30 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
haemorrhoids			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 14 (0.00%)	0 / 30 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
rectal polyp			
alternative dictionary used: MedDRA 20.1			

subjects affected / exposed	0 / 14 (0.00%)	0 / 30 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
cholecystitis acute			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 14 (0.00%)	0 / 30 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cholelithiasis			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 14 (0.00%)	0 / 30 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
gallbladder polyp			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 14 (0.00%)	0 / 30 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
bladder dysfunction			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 14 (0.00%)	0 / 30 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
goitre			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 14 (0.00%)	0 / 30 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
arthralgia			
alternative dictionary used: MedDRA 20.1			

subjects affected / exposed	0 / 14 (0.00%)	1 / 30 (3.33%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 1	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
patellofemoral pain syndrome			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 14 (0.00%)	0 / 30 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
appendicitis			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 14 (0.00%)	0 / 30 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
influenza			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 14 (0.00%)	0 / 30 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pyelonephritis			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 14 (0.00%)	0 / 30 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
urosepsis			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 14 (0.00%)	0 / 30 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Serious adverse events	Placebo ME2 - Post-treatment Phase	Galcanezumab 120mg ME2 - Post-treatment Phase	Galcanezumab 240mg ME2 - Post-treatment Phase
Total subjects affected by serious adverse events			
subjects affected / exposed	2 / 25 (8.00%)	0 / 14 (0.00%)	0 / 20 (0.00%)

number of deaths (all causes)	0	0	0
number of deaths resulting from adverse events	0	0	0
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
adenocarcinoma of the cervix			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed[1]	0 / 18 (0.00%)	0 / 13 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
uterine leiomyoma			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed[2]	0 / 18 (0.00%)	0 / 13 (0.00%)	0 / 14 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
General disorders and administration site conditions			
pyrexia			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 25 (0.00%)	0 / 14 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Respiratory, thoracic and mediastinal disorders			
nasal septum deviation			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 25 (0.00%)	0 / 14 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Psychiatric disorders			
disorientation			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 25 (0.00%)	0 / 14 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
panic attack			
alternative dictionary used: MedDRA 20.1			

subjects affected / exposed	0 / 25 (0.00%)	0 / 14 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
post-traumatic stress disorder			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 25 (0.00%)	0 / 14 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
suicide attempt			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 25 (0.00%)	0 / 14 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Injury, poisoning and procedural complications			
foot fracture			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 25 (0.00%)	0 / 14 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
meniscus injury			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 25 (0.00%)	0 / 14 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
rib fracture			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 25 (0.00%)	0 / 14 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
road traffic accident			
alternative dictionary used: MedDRA 20.1			

subjects affected / exposed	0 / 25 (0.00%)	0 / 14 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Cardiac disorders			
acute myocardial infarction			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 25 (0.00%)	0 / 14 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Nervous system disorders			
generalised tonic-clonic seizure			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 25 (0.00%)	0 / 14 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
headache			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 25 (0.00%)	0 / 14 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
migraine			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	1 / 25 (4.00%)	0 / 14 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
transient ischaemic attack			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 25 (0.00%)	0 / 14 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Gastrointestinal disorders			
gastritis			
alternative dictionary used: MedDRA 20.1			

subjects affected / exposed	0 / 25 (0.00%)	0 / 14 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
haemorrhoids			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 25 (0.00%)	0 / 14 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
rectal polyp			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 25 (0.00%)	0 / 14 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Hepatobiliary disorders			
cholecystitis acute			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	1 / 25 (4.00%)	0 / 14 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 1	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
cholelithiasis			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 25 (0.00%)	0 / 14 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
gallbladder polyp			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 25 (0.00%)	0 / 14 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Renal and urinary disorders			
bladder dysfunction			
alternative dictionary used: MedDRA 20.1			

subjects affected / exposed	0 / 25 (0.00%)	0 / 14 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Endocrine disorders			
goitre			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 25 (0.00%)	0 / 14 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Musculoskeletal and connective tissue disorders			
arthralgia			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 25 (0.00%)	0 / 14 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
patellofemoral pain syndrome			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 25 (0.00%)	0 / 14 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
Infections and infestations			
appendicitis			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 25 (0.00%)	0 / 14 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
influenza			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 25 (0.00%)	0 / 14 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
pyelonephritis			
alternative dictionary used: MedDRA 20.1			

subjects affected / exposed	0 / 25 (0.00%)	0 / 14 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0
urosepsis			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 25 (0.00%)	0 / 14 (0.00%)	0 / 20 (0.00%)
occurrences causally related to treatment / all	0 / 0	0 / 0	0 / 0
deaths causally related to treatment / all	0 / 0	0 / 0	0 / 0

Notes:

[1] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
Justification: Gender based AE occurred only in female participants.

[2] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed to this adverse event. These numbers are expected to be equal.
Justification: Gender based AE occurred only in female participants.

Frequency threshold for reporting non-serious adverse events: 5 %

Non-serious adverse events	Placebo - Treatment Phase	Galcanezumab 120mg - Treatment Phase	Galcanezumab 240mg - Treatment Phase
Total subjects affected by non-serious adverse events			
subjects affected / exposed	150 / 461 (32.54%)	78 / 226 (34.51%)	87 / 228 (38.16%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
skin papilloma			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 461 (0.00%)	0 / 226 (0.00%)	0 / 228 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
contusion			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	3 / 461 (0.65%)	1 / 226 (0.44%)	2 / 228 (0.88%)
occurrences (all)	3	1	2
muscle strain			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	1 / 461 (0.22%)	1 / 226 (0.44%)	1 / 228 (0.44%)
occurrences (all)	1	1	1
Nervous system disorders			

carpal tunnel syndrome alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 461 (0.00%)	0 / 226 (0.00%)	1 / 228 (0.44%)
occurrences (all)	0	0	1
dizziness alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	10 / 461 (2.17%)	8 / 226 (3.54%)	7 / 228 (3.07%)
occurrences (all)	12	10	7
hypoaesthesia alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	2 / 461 (0.43%)	0 / 226 (0.00%)	2 / 228 (0.88%)
occurrences (all)	2	0	2
General disorders and administration site conditions			
injection site pain alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	39 / 461 (8.46%)	21 / 226 (9.29%)	20 / 228 (8.77%)
occurrences (all)	142	100	61
injection site reaction alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 461 (0.00%)	7 / 226 (3.10%)	18 / 228 (7.89%)
occurrences (all)	0	17	25
Gastrointestinal disorders			
abdominal pain upper alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	3 / 461 (0.65%)	4 / 226 (1.77%)	3 / 228 (1.32%)
occurrences (all)	3	5	3
nausea alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	15 / 461 (3.25%)	4 / 226 (1.77%)	3 / 228 (1.32%)
occurrences (all)	15	4	3
vomiting alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	4 / 461 (0.87%)	0 / 226 (0.00%)	2 / 228 (0.88%)
occurrences (all)	4	0	2
Respiratory, thoracic and mediastinal			

disorders			
cough			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	9 / 461 (1.95%)	4 / 226 (1.77%)	3 / 228 (1.32%)
occurrences (all)	9	4	3
vaginal discharge			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed[3]	0 / 393 (0.00%)	0 / 192 (0.00%)	0 / 196 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
insomnia			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	8 / 461 (1.74%)	3 / 226 (1.33%)	0 / 228 (0.00%)
occurrences (all)	9	3	0
Musculoskeletal and connective tissue disorders			
arthralgia			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	5 / 461 (1.08%)	4 / 226 (1.77%)	3 / 228 (1.32%)
occurrences (all)	5	4	3
arthritis			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 461 (0.00%)	0 / 226 (0.00%)	0 / 228 (0.00%)
occurrences (all)	0	0	0
back pain			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	20 / 461 (4.34%)	2 / 226 (0.88%)	5 / 228 (2.19%)
occurrences (all)	24	2	5
foot deformity			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 461 (0.00%)	0 / 226 (0.00%)	0 / 228 (0.00%)
occurrences (all)	0	0	0
intervertebral disc disorder			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 461 (0.00%)	0 / 226 (0.00%)	0 / 228 (0.00%)
occurrences (all)	0	0	0

Infections and infestations			
cystitis			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	5 / 461 (1.08%)	2 / 226 (0.88%)	2 / 228 (0.88%)
occurrences (all)	5	2	2
hordeolum			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	2 / 461 (0.43%)	0 / 226 (0.00%)	0 / 228 (0.00%)
occurrences (all)	2	0	0
influenza			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	14 / 461 (3.04%)	3 / 226 (1.33%)	9 / 228 (3.95%)
occurrences (all)	16	4	9
nasopharyngitis			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	41 / 461 (8.89%)	19 / 226 (8.41%)	16 / 228 (7.02%)
occurrences (all)	49	23	21
pharyngitis			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	1 / 461 (0.22%)	0 / 226 (0.00%)	1 / 228 (0.44%)
occurrences (all)	1	0	1
rhinitis			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	4 / 461 (0.87%)	2 / 226 (0.88%)	1 / 228 (0.44%)
occurrences (all)	4	2	2
upper respiratory tract infection			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	16 / 461 (3.47%)	13 / 226 (5.75%)	12 / 228 (5.26%)
occurrences (all)	19	14	12
vaginal infection			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed[4]	0 / 393 (0.00%)	2 / 192 (1.04%)	1 / 196 (0.51%)
occurrences (all)	0	2	1
vulvovaginitis			
alternative dictionary used: MedDRA 20.1			

subjects affected / exposed[5]	1 / 393 (0.25%)	0 / 192 (0.00%)	0 / 196 (0.00%)
occurrences (all)	1	0	0

Non-serious adverse events	Placebo - Post-treatment Phase	Galcanezumab 120mg - Post-treatment Phase	Galcanezumab 240mg - Post-treatment Phase
Total subjects affected by non-serious adverse events			
subjects affected / exposed	40 / 410 (9.76%)	16 / 212 (7.55%)	13 / 208 (6.25%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
skin papilloma			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 410 (0.00%)	0 / 212 (0.00%)	0 / 208 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
contusion			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 410 (0.00%)	0 / 212 (0.00%)	1 / 208 (0.48%)
occurrences (all)	0	0	1
muscle strain			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	1 / 410 (0.24%)	0 / 212 (0.00%)	0 / 208 (0.00%)
occurrences (all)	1	0	0
Nervous system disorders			
carpal tunnel syndrome			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	1 / 410 (0.24%)	0 / 212 (0.00%)	0 / 208 (0.00%)
occurrences (all)	1	0	0
dizziness			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 410 (0.00%)	0 / 212 (0.00%)	0 / 208 (0.00%)
occurrences (all)	0	0	0
hypoaesthesia			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 410 (0.00%)	0 / 212 (0.00%)	0 / 208 (0.00%)
occurrences (all)	0	0	0
General disorders and administration site conditions			

injection site pain			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 410 (0.00%)	0 / 212 (0.00%)	0 / 208 (0.00%)
occurrences (all)	0	0	0
injection site reaction			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 410 (0.00%)	0 / 212 (0.00%)	0 / 208 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
abdominal pain upper			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 410 (0.00%)	0 / 212 (0.00%)	1 / 208 (0.48%)
occurrences (all)	0	0	2
nausea			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	1 / 410 (0.24%)	0 / 212 (0.00%)	1 / 208 (0.48%)
occurrences (all)	1	0	1
vomiting			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 410 (0.00%)	0 / 212 (0.00%)	0 / 208 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
cough			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	2 / 410 (0.49%)	0 / 212 (0.00%)	1 / 208 (0.48%)
occurrences (all)	2	0	1
vaginal discharge			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed[3]	0 / 349 (0.00%)	1 / 179 (0.56%)	0 / 181 (0.00%)
occurrences (all)	0	1	0
Psychiatric disorders			
insomnia			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	3 / 410 (0.73%)	0 / 212 (0.00%)	0 / 208 (0.00%)
occurrences (all)	3	0	0

Musculoskeletal and connective tissue disorders			
arthralgia			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	1 / 410 (0.24%)	2 / 212 (0.94%)	0 / 208 (0.00%)
occurrences (all)	1	2	0
arthritis			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 410 (0.00%)	0 / 212 (0.00%)	1 / 208 (0.48%)
occurrences (all)	0	0	1
back pain			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	4 / 410 (0.98%)	2 / 212 (0.94%)	1 / 208 (0.48%)
occurrences (all)	4	2	1
foot deformity			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 410 (0.00%)	0 / 212 (0.00%)	0 / 208 (0.00%)
occurrences (all)	0	0	0
intervertebral disc disorder			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 410 (0.00%)	0 / 212 (0.00%)	0 / 208 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
cystitis			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	1 / 410 (0.24%)	0 / 212 (0.00%)	0 / 208 (0.00%)
occurrences (all)	1	0	0
hordeolum			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 410 (0.00%)	0 / 212 (0.00%)	0 / 208 (0.00%)
occurrences (all)	0	0	0
influenza			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	5 / 410 (1.22%)	1 / 212 (0.47%)	1 / 208 (0.48%)
occurrences (all)	5	1	1
nasopharyngitis			

alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	18 / 410 (4.39%)	5 / 212 (2.36%)	4 / 208 (1.92%)
occurrences (all)	19	5	5
pharyngitis			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	2 / 410 (0.49%)	1 / 212 (0.47%)	1 / 208 (0.48%)
occurrences (all)	2	1	1
rhinitis			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 410 (0.00%)	1 / 212 (0.47%)	0 / 208 (0.00%)
occurrences (all)	0	1	0
upper respiratory tract infection			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	3 / 410 (0.73%)	4 / 212 (1.89%)	2 / 208 (0.96%)
occurrences (all)	4	5	2
vaginal infection			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed[4]	2 / 349 (0.57%)	0 / 179 (0.00%)	0 / 181 (0.00%)
occurrences (all)	2	0	0
vulvovaginitis			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed[5]	0 / 349 (0.00%)	0 / 179 (0.00%)	0 / 181 (0.00%)
occurrences (all)	0	0	0

Non-serious adverse events	Galcanezumab 120mg ME2 - Treatment Phase	Placebo ME2 - Treatment Phase	Galcanezumab 240mg ME2 - Treatment Phase
Total subjects affected by non-serious adverse events			
subjects affected / exposed	9 / 14 (64.29%)	10 / 30 (33.33%)	9 / 20 (45.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
skin papilloma			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 30 (0.00%)	0 / 20 (0.00%)
occurrences (all)	1	0	0
Injury, poisoning and procedural complications			

contusion			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 14 (0.00%)	0 / 30 (0.00%)	2 / 20 (10.00%)
occurrences (all)	0	0	2
muscle strain			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 30 (0.00%)	0 / 20 (0.00%)
occurrences (all)	1	0	0
Nervous system disorders			
carpal tunnel syndrome			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 30 (0.00%)	0 / 20 (0.00%)
occurrences (all)	1	0	0
dizziness			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 30 (0.00%)	0 / 20 (0.00%)
occurrences (all)	1	0	0
hypoaesthesia			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 30 (0.00%)	0 / 20 (0.00%)
occurrences (all)	1	0	0
General disorders and administration site conditions			
injection site pain			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 14 (0.00%)	0 / 30 (0.00%)	0 / 20 (0.00%)
occurrences (all)	0	0	0
injection site reaction			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 30 (0.00%)	3 / 20 (15.00%)
occurrences (all)	1	0	12
Gastrointestinal disorders			
abdominal pain upper			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 30 (0.00%)	0 / 20 (0.00%)
occurrences (all)	1	0	0

nausea			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 30 (0.00%)	0 / 20 (0.00%)
occurrences (all)	1	0	0
vomiting			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 14 (0.00%)	0 / 30 (0.00%)	0 / 20 (0.00%)
occurrences (all)	0	0	0
Respiratory, thoracic and mediastinal disorders			
cough			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 14 (0.00%)	2 / 30 (6.67%)	1 / 20 (5.00%)
occurrences (all)	0	3	1
vaginal discharge			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed[3]	1 / 13 (7.69%)	0 / 22 (0.00%)	0 / 14 (0.00%)
occurrences (all)	2	0	0
Psychiatric disorders			
insomnia			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 30 (0.00%)	1 / 20 (5.00%)
occurrences (all)	1	0	1
Musculoskeletal and connective tissue disorders			
arthralgia			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	1 / 14 (7.14%)	2 / 30 (6.67%)	0 / 20 (0.00%)
occurrences (all)	1	2	0
arthritis			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 30 (0.00%)	0 / 20 (0.00%)
occurrences (all)	1	0	0
back pain			
alternative dictionary used: MedDRA 20.1			

subjects affected / exposed	2 / 14 (14.29%)	1 / 30 (3.33%)	0 / 20 (0.00%)
occurrences (all)	3	1	0
foot deformity			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 14 (0.00%)	0 / 30 (0.00%)	0 / 20 (0.00%)
occurrences (all)	0	0	0
intervertebral disc disorder			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 14 (0.00%)	0 / 30 (0.00%)	0 / 20 (0.00%)
occurrences (all)	0	0	0
Infections and infestations			
cystitis			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 30 (0.00%)	0 / 20 (0.00%)
occurrences (all)	1	0	0
hordeolum			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	1 / 14 (7.14%)	0 / 30 (0.00%)	0 / 20 (0.00%)
occurrences (all)	1	0	0
influenza			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 14 (0.00%)	2 / 30 (6.67%)	0 / 20 (0.00%)
occurrences (all)	0	2	0
nasopharyngitis			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	2 / 14 (14.29%)	1 / 30 (3.33%)	2 / 20 (10.00%)
occurrences (all)	2	1	3
pharyngitis			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 14 (0.00%)	2 / 30 (6.67%)	0 / 20 (0.00%)
occurrences (all)	0	2	0
rhinitis			
alternative dictionary used: MedDRA 20.1			

subjects affected / exposed	1 / 14 (7.14%)	0 / 30 (0.00%)	0 / 20 (0.00%)
occurrences (all)	1	0	0
upper respiratory tract infection			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	3 / 14 (21.43%)	2 / 30 (6.67%)	1 / 20 (5.00%)
occurrences (all)	4	2	1
vaginal infection			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed[4]	0 / 13 (0.00%)	0 / 22 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1
vulvovaginitis			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed[5]	0 / 13 (0.00%)	0 / 22 (0.00%)	1 / 14 (7.14%)
occurrences (all)	0	0	1

Non-serious adverse events	Placebo ME2 - Post-treatment Phase	Galcanezumab 120mg ME2 - Post-treatment Phase	Galcanezumab 240mg ME2 - Post-treatment Phase
Total subjects affected by non-serious adverse events			
subjects affected / exposed	3 / 25 (12.00%)	6 / 14 (42.86%)	0 / 20 (0.00%)
Neoplasms benign, malignant and unspecified (incl cysts and polyps)			
skin papilloma			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 25 (0.00%)	0 / 14 (0.00%)	0 / 20 (0.00%)
occurrences (all)	0	0	0
Injury, poisoning and procedural complications			
contusion			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 25 (0.00%)	0 / 14 (0.00%)	0 / 20 (0.00%)
occurrences (all)	0	0	0
muscle strain			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 25 (0.00%)	0 / 14 (0.00%)	0 / 20 (0.00%)
occurrences (all)	0	0	0
Nervous system disorders			

carpal tunnel syndrome			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 25 (0.00%)	0 / 14 (0.00%)	0 / 20 (0.00%)
occurrences (all)	0	0	0
dizziness			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 25 (0.00%)	1 / 14 (7.14%)	0 / 20 (0.00%)
occurrences (all)	0	1	0
hypoaesthesia			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	1 / 25 (4.00%)	0 / 14 (0.00%)	0 / 20 (0.00%)
occurrences (all)	1	0	0
General disorders and administration site conditions			
injection site pain			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 25 (0.00%)	0 / 14 (0.00%)	0 / 20 (0.00%)
occurrences (all)	0	0	0
injection site reaction			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 25 (0.00%)	0 / 14 (0.00%)	0 / 20 (0.00%)
occurrences (all)	0	0	0
Gastrointestinal disorders			
abdominal pain upper			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	1 / 25 (4.00%)	0 / 14 (0.00%)	0 / 20 (0.00%)
occurrences (all)	1	0	0
nausea			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 25 (0.00%)	1 / 14 (7.14%)	0 / 20 (0.00%)
occurrences (all)	0	1	0
vomiting			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 25 (0.00%)	1 / 14 (7.14%)	0 / 20 (0.00%)
occurrences (all)	0	1	0
Respiratory, thoracic and mediastinal			

disorders			
cough			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 25 (0.00%)	0 / 14 (0.00%)	0 / 20 (0.00%)
occurrences (all)	0	0	0
vaginal discharge			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed[3]	0 / 18 (0.00%)	0 / 13 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
Psychiatric disorders			
insomnia			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 25 (0.00%)	0 / 14 (0.00%)	0 / 20 (0.00%)
occurrences (all)	0	0	0
Musculoskeletal and connective tissue disorders			
arthralgia			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 25 (0.00%)	1 / 14 (7.14%)	0 / 20 (0.00%)
occurrences (all)	0	1	0
arthritis			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 25 (0.00%)	0 / 14 (0.00%)	0 / 20 (0.00%)
occurrences (all)	0	0	0
back pain			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	1 / 25 (4.00%)	1 / 14 (7.14%)	0 / 20 (0.00%)
occurrences (all)	1	1	0
foot deformity			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 25 (0.00%)	1 / 14 (7.14%)	0 / 20 (0.00%)
occurrences (all)	0	1	0
intervertebral disc disorder			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 25 (0.00%)	1 / 14 (7.14%)	0 / 20 (0.00%)
occurrences (all)	0	1	0

Infections and infestations			
cystitis			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 25 (0.00%)	0 / 14 (0.00%)	0 / 20 (0.00%)
occurrences (all)	0	0	0
hordeolum			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 25 (0.00%)	0 / 14 (0.00%)	0 / 20 (0.00%)
occurrences (all)	0	0	0
influenza			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 25 (0.00%)	0 / 14 (0.00%)	0 / 20 (0.00%)
occurrences (all)	0	0	0
nasopharyngitis			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 25 (0.00%)	1 / 14 (7.14%)	0 / 20 (0.00%)
occurrences (all)	0	1	0
pharyngitis			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 25 (0.00%)	0 / 14 (0.00%)	0 / 20 (0.00%)
occurrences (all)	0	0	0
rhinitis			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	1 / 25 (4.00%)	0 / 14 (0.00%)	0 / 20 (0.00%)
occurrences (all)	1	0	0
upper respiratory tract infection			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed	0 / 25 (0.00%)	1 / 14 (7.14%)	0 / 20 (0.00%)
occurrences (all)	0	1	0
vaginal infection			
alternative dictionary used: MedDRA 20.1			
subjects affected / exposed[4]	0 / 18 (0.00%)	0 / 13 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0
vulvovaginitis			
alternative dictionary used: MedDRA 20.1			

subjects affected / exposed[5]	0 / 18 (0.00%)	0 / 13 (0.00%)	0 / 14 (0.00%)
occurrences (all)	0	0	0

Notes:

[3] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Gender based AE occurred only in female participants.

[4] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Gender based AE occurred only in female participants.

[5] - The number of subjects exposed to this adverse event is less than the total number of subjects exposed for the reporting group. These numbers are expected to be equal.
Justification: Gender based AE occurred only in female participants.

More information

Substantial protocol amendments (globally)

Were there any global substantial amendments to the protocol? Yes

Date	Amendment
22 January 2016	Exclusion criteria updated to excluded patients with a prior lifetime history of stroke to provide additional safeguards for patients who may be at risk for stroke. Added text to indicate that neurological examinations will be conducted to assess for possible cerebrovascular events, along with instructions for appropriate follow-up. Reworded the procedures associated with emergency unblinding. Modified treatment discontinuation criteria. Added clarification on the statistical model to be used for subgroup analyses. Updated the Schedule of Activities and footnotes to reflect added neurological examinations.

Notes:

Interruptions (globally)

Were there any global interruptions to the trial? No

Limitations and caveats

None reported